{"product_id":"lantheus-business-model-canvas","title":"Lantheus Medical Imaging Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the strategic business model blueprint for scaling diagnostic imaging innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Lantheus Medical Imaging’s business model with our concise Business Model Canvas summary—three to five sentences that map value propositions, key partners, and revenue streams. This snapshot reveals how Lantheus scales diagnostic innovation and sustains competitive advantage. Purchase the complete, editable Canvas in Word and Excel for a section-by-section breakdown, actionable insights, and pitch-ready slides.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRadiopharmacy networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnerships with national and regional radiopharmacies secure last-mile compounding and timely dose delivery, enabling same-day PET\/SPECT supply to many centers; in the US ~2 million PET scans were performed in 2024, underscoring demand for rapid logistics. Joint forecasting with radiopharmacies improves dose availability and reduces waste, lowering expired-dose losses. Co-marketing and training programs increase site compliance on ordering and handling, raising on-time utilization. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIsotope and raw material suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSecuring consistent supplies of Mo-99, I-123, F-18 and specialty precursors is critical to Lantheus’ uninterrupted radiopharmaceutical production and patient delivery. Long-term supply contracts with isotope producers and chemical vendors reduce volatility and price risk while technical collaboration improves yields and shelf life through process optimization. Dual sourcing and geographic diversification strengthen resilience against single-source outages and regulatory disruptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma and biotech co-development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlliances with pharma and biotech accelerate Lantheus theranostic and companion diagnostic programs, leveraging shared trials and biomarkers to de-risk development and expand indications. Shared studies improve patient accrual and endpoint validation, with partnerships reportedly shortening development timelines by about 30% in recent oncology programs. Licensing deals monetize platform technologies and recurring royalties, while joint field teams accelerate clinician adoption and formulary uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and clinical research centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLeading academic and clinical centers provide trial sites and KOL validation, accelerating adoption of Lantheus radiopharmaceuticals. Investigator-initiated studies broaden evidence and real-world data, with increasing 2024 publications. Protocol feedback refines labeling and use cases. Publications underpin guideline inclusion and reimbursement discussions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrial sites \u0026amp; KOL validation\u003c\/li\u003e\n\u003cli\u003eInvestigator-initiated real-world evidence\u003c\/li\u003e\n\u003cli\u003eProtocol-driven label refinement\u003c\/li\u003e\n\u003cli\u003ePublications → guidelines \u0026amp; reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory, payers, and GPO\/distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEarly engagement with regulators streamlines approvals and reduces post-market study burdens, enabling faster commercial launch and lower compliance costs.\u003c\/p\u003e\n\u003cp\u003eStrong payer and GPO relationships secure coverage, appropriate coding and formulary access, improving reimbursement predictability for Lantheus products.\u003c\/p\u003e\n\u003cp\u003eDistribution partners extend cold-chain logistics and regulatory compliance into regional markets, crucial for radiopharmaceutical delivery.\u003c\/p\u003e\n\u003cp\u003eCollaborative HTA submissions with payers and providers strengthen economic positioning and support value dossiers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory engagement: faster approvals, fewer post-market commitments\u003c\/li\u003e\n\u003cli\u003ePayers\/GPOs: coverage, coding, formulary access\u003c\/li\u003e\n\u003cli\u003eDistributors: cold-chain reach, compliance\u003c\/li\u003e\n\u003cli\u003eHTA collaboration: stronger economic case\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSame-day PET\/SPECT delivery supports \u003cstrong\u003e~2,000,000\u003c\/strong\u003e US scans in 2024; theranostics \u003cstrong\u003e~30%\u003c\/strong\u003e faster\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartnerships with national\/regional radiopharmacies ensure same-day PET\/SPECT delivery supporting ~2,000,000 US PET scans in 2024, reducing waste via joint forecasting. Long-term isotope and precursor contracts plus dual sourcing lower outage and price risk. Pharma\/biotech alliances cut theranostic development timelines ~30% in recent oncology programs and expand indications. Academic KOLs and payers accelerate adoption and reimbursement.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadiopharmacies\u003c\/td\u003e\n\u003ctd\u003eLast-mile compounding\/logistics\u003c\/td\u003e\n\u003ctd\u003eSupports ~2,000,000 US PET scans\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIsotope suppliers\u003c\/td\u003e\n\u003ctd\u003eSupply stability\u003c\/td\u003e\n\u003ctd\u003eLong-term contracts, dual sourcing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\/biotech\u003c\/td\u003e\n\u003ctd\u003eCo-development\/licensing\u003c\/td\u003e\n\u003ctd\u003e~30% faster oncology timelines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas tailored to Lantheus Medical Imaging, detailing customer segments (hospitals, imaging centers, pharma partners), channels, and value propositions around radiopharmaceuticals and diagnostic imaging solutions. Organized into 9 BMC blocks with competitive advantage and SWOT insights for presentations, investor discussions, and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Lantheus Medical Imaging’s strategy into a digestible one-page Business Model Canvas that quickly identifies core components, eases stakeholder alignment, and saves hours of structuring for boardrooms or team workshops.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and radiochemistry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and radiochemistry drive discovery and optimization of tracers and theranostics, building on commercialized agents like PYLARIFY (approved 2021) to expand the pipeline. Preclinical GLP validation confirms targeting, safety and dosimetry across rodent and NHP models. Scale-up translates processes to cGMP manufacturing with radiochemical purity targets typically above 95%. Continuous process improvement enhances stability and shelf-life for clinical supply.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesigning and running Phase 1–4 trials generates the efficacy and safety evidence required for regulatory approval and label claims. Companion studies validate diagnostic accuracy and link imaging results to clinical outcomes. Prospective registries capture real-world performance and safety, and aggregated clinical data packages underpin labeling and reimbursement submissions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ecGMP manufacturing and QC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBatch production, sterile filling and release testing ensure product quality and traceability, with typical radiopharmaceutical release sampling completed within 60 minutes to match short physical half-lives (eg technetium-99m 6 hours). Rapid cycle times and on-demand batches align production capacity with clinical scheduling. Qualified equipment and validated methods meet FDA cGMP requirements, and annual QA audits plus continuous CAPA tracking sustain compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePreparation of INDs, NDAs and supplements is core to regulatory approvals, with FDA standard review timelines around 10 months; HEOR builds value dossiers to support payer decisions and coverage (decisions often take 6–12 months); coding, coverage and payment advocacy drive adoption; robust post-market safety surveillance and over 100 active REMS programs preserve trust.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIND\/NDA prep \u0026amp; supplements\u003c\/li\u003e\n\u003cli\u003eHEOR \u0026amp; value dossiers\u003c\/li\u003e\n\u003cli\u003eCoding, coverage \u0026amp; payment advocacy\u003c\/li\u003e\n\u003cli\u003ePost-market safety \u0026amp; REMS\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDirect sales and medical education drive demand for Lantheus' imaging agents, supporting clinical uptake and a commercial network that contributed to 2024 revenue of $653 million. Cold-chain coordination with radiopharmacies and third-party couriers ensures on-time delivery of temperature-sensitive doses. Forecasting, slot management and digital ordering reduce stockouts and improve customer experience.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $653M\u003c\/li\u003e\n\u003cli\u003eCold-chain coordination: real-time tracking\u003c\/li\u003e\n\u003cli\u003eForecasting \u0026amp; slot mgmt: fewer stockouts\u003c\/li\u003e\n\u003cli\u003eDigital ordering: faster support \u0026amp; lower lead times\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ecGMP tracers: \u003cstrong\u003e\u0026gt;95%\u003c\/strong\u003e purity, \u003cstrong\u003e60\u003c\/strong\u003e-min release, FDA ~\u003cstrong\u003e10\u003c\/strong\u003emo, \u003cstrong\u003e$653M\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and radiochemistry optimize tracers (eg PYLARIFY) with cGMP scale-up targeting radiochemical purity \u0026gt;95% and release sampling within 60 minutes to match short half-lives (99mTc 6h). Clinical trials (Ph1–4) and registries generate safety\/efficacy evidence; FDA review ~10 months, payer decisions 6–12 months. Manufacturing, cold‑chain logistics and direct sales supported 2024 revenue of $653M and \u0026gt;100 active REMS programs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$653M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadiochemical purity target\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRelease sampling window\u003c\/td\u003e\n\u003ctd\u003e~60 min\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA review\u003c\/td\u003e\n\u003ctd\u003e~10 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer decision\u003c\/td\u003e\n\u003ctd\u003e6–12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the exact Lantheus Medical Imaging Business Model Canvas you will receive—no mockup, no filler. Upon purchase, you’ll instantly download the complete, editable file formatted exactly as shown, ready for presentation or analysis in Word and Excel. You’ll get full access to all content and pages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56161630093689,"sku":"lantheus-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/lantheus-business-model-canvas.png?v=1762695454","url":"https:\/\/portersfiveforce.com\/products\/lantheus-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}